Almirall stock slips after recent rally as investors watch earnings momentum

Published on 09/19/2026 at 18:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Almirall stock closed at EUR 10.44 on September 18, 2026 on Bolsa de Madrid, down 1.51 percent after testing short term resistance earlier in the week. The dermatology specialist continues to build on recent gains as investors look ahead to the next earnings update.

Pop-Art-Comic einer Dermatologin, die mit Lupe die Haut einer Patientin untersucht — Almirall S.A. (ES0157097017) inspiriert Pop-Art-Comic-Szene einer Dermatologin bei Hautuntersuchung mit Lupe, farbenfroh, Illustration mit AI erstellt.

Almirall stock (ISIN ES0157097017) finished the September 18, 2026 session on Bolsa de Madrid at EUR 10.44, a daily decline of 1.51 percent after a drop of EUR 0.16 from the prior close.

Stock retreats after resistance test

According to Bolsamania data as of September 18, 2026, Almirall shares ended the day at EUR 10.44, down 1.51 percent, implying a prior closing level of around EUR 10.60 on the same venue.

In a recent technical commentary dated September 15, 2026, Bolsamania reported that Almirall saw strong gains as the stock broke through short term resistance around EUR 10.54, highlighting increased buying interest around that level.

Chart and valuation context

Another technical overview for Almirall on Bolsamania includes market capitalization information alongside the quote, indicating that the company is valued in the mid single digit billion euro range as of the recent trading sessions on Bolsa de Madrid.

For investors, the move from a breakout above EUR 10.54 on September 15, 2026 to a close at EUR 10.44 on September 18, 2026 means the stock has given back part of its short term gains but remains close to that resistance-turned-support area in the near term.

Almirall stock price and investor angle

Based on the latest available Bolsa de Madrid quote for September 18, 2026, Almirall stock trades at EUR 10.44, keeping the company in the mid cap segment of the Spanish healthcare sector and leaving room for future moves as new financial results and guidance are published.